L'ipertensione arteriosa polmonare. Parte I: Patobiologia, fisiopatologia, aspetti clinici e diagnostici

Translated title of the contribution: Pulmonary arterial hypertension. Part I. Pathobiologic, pathophysiologic, clinical and diagnostic aspects

Massimiliano Palazzini, Alessandra Manes, Luca Negro, Alessandro Marinelli, Enri Leci, Simona Gambetti, Cristina Bachetti, Elena Beciani, Elisa Conficoni, Angelo Branzi, Nazzareno Galiè

Research output: Contribution to journalArticle

Abstract

Pulmonary hypertension is a pathophysiologic condition characterized by the increase of mean pulmonary arterial pressure ≥25 mmHg. A concomitant increase of pulmonary wedge pressure >15 mmHg may be present (post-capillary pulmonary hypertension) or not (precapillary pulmonary hypertension). The increase of pulmonary arterial pressure and of pulmonary vascular resistance and consequent elevation of the right ventricular afterload lead to right ventricular failure after variable periods of time. Pulmonary hypertension is present in multiple clinical conditions which have been classified in five groups. Pulmonary arterial hypertension (group 1) includes the familial and the idiopathic form and the forms associated with anorexigen drug use, connective tissue diseases, congenital heart diseases, HIV infection and portal hypertension. Group 2 includes all left heart diseases characterized by the increase of left atrial pressure and pulmonary wedge pressure (post-capillary pulmonary hypertension). Group 3 includes parenchymal lung diseases (chronic obstructive lung disease, lung fibrosis, ecc). Chronic thromboembolic pulmonary hypertension (group 4) is characterized by the obstruction of elastic pulmonary arteries at different levels by organized thromboembolism. Group 5 includes heterogeneous conditions such as sarcoidosis and histiocytosis X. These clinical groups are characterized by different pathobiologic and pathophysiologic mechanisms and therapeutic strategies. The exact pathobiologic mechanisms leading to pulmonary arterial hypertension (group 1) are unknown. Genetic factors (inheritable forms), predisposing factors (female gender) and exogenous factors (drugs, antibodies, viruses, congenital heart disease, etc). Endothelial dysfunction of lung microcirculation is invariably present and is characterized by the reduction of vasodilator and antiproliferative substances (prostacyclin, nitric oxide) and by the increase of vasoconstrictor and mitogenic factors (endothelin, thromboxane A2). Current approved therapies are targeted to the correction of this imbalance, which leads to the progressive increase of pulmonary vascular resistance. Different therapeutic strategies that are effective in diverse groups require an appropriate diagnostic algorithm in order to identify the precise group and specific conditions within the group. Evaluation of vasoreactivity and assessment of the severity of functional and hemodynamic changes are also required in pulmonary arterial hypertension for an appropriate therapeutic decision-making and estimate of results.

Original languageItalian
Pages (from-to)271-300
Number of pages30
JournalGiornale Italiano di Cardiologia
Volume10
Issue number5
Publication statusPublished - May 2009

Fingerprint

Pulmonary Hypertension
Heart Diseases
Lung
Pulmonary Wedge Pressure
Vascular Resistance
Arterial Pressure
Langerhans Cell Histiocytosis
Thromboxane A2
Connective Tissue Diseases
Atrial Pressure
Thromboembolism
Endothelins
Portal Hypertension
Vasoconstrictor Agents
Epoprostenol
Therapeutics
Microcirculation
Sarcoidosis
Vasodilator Agents
Causality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Palazzini, M., Manes, A., Negro, L., Marinelli, A., Leci, E., Gambetti, S., ... Galiè, N. (2009). L'ipertensione arteriosa polmonare. Parte I: Patobiologia, fisiopatologia, aspetti clinici e diagnostici. Giornale Italiano di Cardiologia, 10(5), 271-300.

L'ipertensione arteriosa polmonare. Parte I : Patobiologia, fisiopatologia, aspetti clinici e diagnostici. / Palazzini, Massimiliano; Manes, Alessandra; Negro, Luca; Marinelli, Alessandro; Leci, Enri; Gambetti, Simona; Bachetti, Cristina; Beciani, Elena; Conficoni, Elisa; Branzi, Angelo; Galiè, Nazzareno.

In: Giornale Italiano di Cardiologia, Vol. 10, No. 5, 05.2009, p. 271-300.

Research output: Contribution to journalArticle

Palazzini, M, Manes, A, Negro, L, Marinelli, A, Leci, E, Gambetti, S, Bachetti, C, Beciani, E, Conficoni, E, Branzi, A & Galiè, N 2009, 'L'ipertensione arteriosa polmonare. Parte I: Patobiologia, fisiopatologia, aspetti clinici e diagnostici', Giornale Italiano di Cardiologia, vol. 10, no. 5, pp. 271-300.
Palazzini, Massimiliano ; Manes, Alessandra ; Negro, Luca ; Marinelli, Alessandro ; Leci, Enri ; Gambetti, Simona ; Bachetti, Cristina ; Beciani, Elena ; Conficoni, Elisa ; Branzi, Angelo ; Galiè, Nazzareno. / L'ipertensione arteriosa polmonare. Parte I : Patobiologia, fisiopatologia, aspetti clinici e diagnostici. In: Giornale Italiano di Cardiologia. 2009 ; Vol. 10, No. 5. pp. 271-300.
@article{9f1339ae27434b0b9ed9ebf90665f2f7,
title = "L'ipertensione arteriosa polmonare. Parte I: Patobiologia, fisiopatologia, aspetti clinici e diagnostici",
abstract = "Pulmonary hypertension is a pathophysiologic condition characterized by the increase of mean pulmonary arterial pressure ≥25 mmHg. A concomitant increase of pulmonary wedge pressure >15 mmHg may be present (post-capillary pulmonary hypertension) or not (precapillary pulmonary hypertension). The increase of pulmonary arterial pressure and of pulmonary vascular resistance and consequent elevation of the right ventricular afterload lead to right ventricular failure after variable periods of time. Pulmonary hypertension is present in multiple clinical conditions which have been classified in five groups. Pulmonary arterial hypertension (group 1) includes the familial and the idiopathic form and the forms associated with anorexigen drug use, connective tissue diseases, congenital heart diseases, HIV infection and portal hypertension. Group 2 includes all left heart diseases characterized by the increase of left atrial pressure and pulmonary wedge pressure (post-capillary pulmonary hypertension). Group 3 includes parenchymal lung diseases (chronic obstructive lung disease, lung fibrosis, ecc). Chronic thromboembolic pulmonary hypertension (group 4) is characterized by the obstruction of elastic pulmonary arteries at different levels by organized thromboembolism. Group 5 includes heterogeneous conditions such as sarcoidosis and histiocytosis X. These clinical groups are characterized by different pathobiologic and pathophysiologic mechanisms and therapeutic strategies. The exact pathobiologic mechanisms leading to pulmonary arterial hypertension (group 1) are unknown. Genetic factors (inheritable forms), predisposing factors (female gender) and exogenous factors (drugs, antibodies, viruses, congenital heart disease, etc). Endothelial dysfunction of lung microcirculation is invariably present and is characterized by the reduction of vasodilator and antiproliferative substances (prostacyclin, nitric oxide) and by the increase of vasoconstrictor and mitogenic factors (endothelin, thromboxane A2). Current approved therapies are targeted to the correction of this imbalance, which leads to the progressive increase of pulmonary vascular resistance. Different therapeutic strategies that are effective in diverse groups require an appropriate diagnostic algorithm in order to identify the precise group and specific conditions within the group. Evaluation of vasoreactivity and assessment of the severity of functional and hemodynamic changes are also required in pulmonary arterial hypertension for an appropriate therapeutic decision-making and estimate of results.",
keywords = "Classification, Diagnosis, Heart catheterization, Prognosis, Pulmonary hypertension",
author = "Massimiliano Palazzini and Alessandra Manes and Luca Negro and Alessandro Marinelli and Enri Leci and Simona Gambetti and Cristina Bachetti and Elena Beciani and Elisa Conficoni and Angelo Branzi and Nazzareno Gali{\`e}",
year = "2009",
month = "5",
language = "Italian",
volume = "10",
pages = "271--300",
journal = "Giornale Italiano di Cardiologia",
issn = "1827-6806",
publisher = "CEPI s.r.l.",
number = "5",

}

TY - JOUR

T1 - L'ipertensione arteriosa polmonare. Parte I

T2 - Patobiologia, fisiopatologia, aspetti clinici e diagnostici

AU - Palazzini, Massimiliano

AU - Manes, Alessandra

AU - Negro, Luca

AU - Marinelli, Alessandro

AU - Leci, Enri

AU - Gambetti, Simona

AU - Bachetti, Cristina

AU - Beciani, Elena

AU - Conficoni, Elisa

AU - Branzi, Angelo

AU - Galiè, Nazzareno

PY - 2009/5

Y1 - 2009/5

N2 - Pulmonary hypertension is a pathophysiologic condition characterized by the increase of mean pulmonary arterial pressure ≥25 mmHg. A concomitant increase of pulmonary wedge pressure >15 mmHg may be present (post-capillary pulmonary hypertension) or not (precapillary pulmonary hypertension). The increase of pulmonary arterial pressure and of pulmonary vascular resistance and consequent elevation of the right ventricular afterload lead to right ventricular failure after variable periods of time. Pulmonary hypertension is present in multiple clinical conditions which have been classified in five groups. Pulmonary arterial hypertension (group 1) includes the familial and the idiopathic form and the forms associated with anorexigen drug use, connective tissue diseases, congenital heart diseases, HIV infection and portal hypertension. Group 2 includes all left heart diseases characterized by the increase of left atrial pressure and pulmonary wedge pressure (post-capillary pulmonary hypertension). Group 3 includes parenchymal lung diseases (chronic obstructive lung disease, lung fibrosis, ecc). Chronic thromboembolic pulmonary hypertension (group 4) is characterized by the obstruction of elastic pulmonary arteries at different levels by organized thromboembolism. Group 5 includes heterogeneous conditions such as sarcoidosis and histiocytosis X. These clinical groups are characterized by different pathobiologic and pathophysiologic mechanisms and therapeutic strategies. The exact pathobiologic mechanisms leading to pulmonary arterial hypertension (group 1) are unknown. Genetic factors (inheritable forms), predisposing factors (female gender) and exogenous factors (drugs, antibodies, viruses, congenital heart disease, etc). Endothelial dysfunction of lung microcirculation is invariably present and is characterized by the reduction of vasodilator and antiproliferative substances (prostacyclin, nitric oxide) and by the increase of vasoconstrictor and mitogenic factors (endothelin, thromboxane A2). Current approved therapies are targeted to the correction of this imbalance, which leads to the progressive increase of pulmonary vascular resistance. Different therapeutic strategies that are effective in diverse groups require an appropriate diagnostic algorithm in order to identify the precise group and specific conditions within the group. Evaluation of vasoreactivity and assessment of the severity of functional and hemodynamic changes are also required in pulmonary arterial hypertension for an appropriate therapeutic decision-making and estimate of results.

AB - Pulmonary hypertension is a pathophysiologic condition characterized by the increase of mean pulmonary arterial pressure ≥25 mmHg. A concomitant increase of pulmonary wedge pressure >15 mmHg may be present (post-capillary pulmonary hypertension) or not (precapillary pulmonary hypertension). The increase of pulmonary arterial pressure and of pulmonary vascular resistance and consequent elevation of the right ventricular afterload lead to right ventricular failure after variable periods of time. Pulmonary hypertension is present in multiple clinical conditions which have been classified in five groups. Pulmonary arterial hypertension (group 1) includes the familial and the idiopathic form and the forms associated with anorexigen drug use, connective tissue diseases, congenital heart diseases, HIV infection and portal hypertension. Group 2 includes all left heart diseases characterized by the increase of left atrial pressure and pulmonary wedge pressure (post-capillary pulmonary hypertension). Group 3 includes parenchymal lung diseases (chronic obstructive lung disease, lung fibrosis, ecc). Chronic thromboembolic pulmonary hypertension (group 4) is characterized by the obstruction of elastic pulmonary arteries at different levels by organized thromboembolism. Group 5 includes heterogeneous conditions such as sarcoidosis and histiocytosis X. These clinical groups are characterized by different pathobiologic and pathophysiologic mechanisms and therapeutic strategies. The exact pathobiologic mechanisms leading to pulmonary arterial hypertension (group 1) are unknown. Genetic factors (inheritable forms), predisposing factors (female gender) and exogenous factors (drugs, antibodies, viruses, congenital heart disease, etc). Endothelial dysfunction of lung microcirculation is invariably present and is characterized by the reduction of vasodilator and antiproliferative substances (prostacyclin, nitric oxide) and by the increase of vasoconstrictor and mitogenic factors (endothelin, thromboxane A2). Current approved therapies are targeted to the correction of this imbalance, which leads to the progressive increase of pulmonary vascular resistance. Different therapeutic strategies that are effective in diverse groups require an appropriate diagnostic algorithm in order to identify the precise group and specific conditions within the group. Evaluation of vasoreactivity and assessment of the severity of functional and hemodynamic changes are also required in pulmonary arterial hypertension for an appropriate therapeutic decision-making and estimate of results.

KW - Classification

KW - Diagnosis

KW - Heart catheterization

KW - Prognosis

KW - Pulmonary hypertension

UR - http://www.scopus.com/inward/record.url?scp=65649113645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65649113645&partnerID=8YFLogxK

M3 - Articolo

C2 - 19537440

AN - SCOPUS:65649113645

VL - 10

SP - 271

EP - 300

JO - Giornale Italiano di Cardiologia

JF - Giornale Italiano di Cardiologia

SN - 1827-6806

IS - 5

ER -